Centre for Digestive Diseases

What Centre for Digestive Diseases does

Centre for Digestive Diseases (CDD) is a privately held specialist gastroenterology clinic founded in 1984 by Prof. Thomas Borody in Sydney, Australia. The clinic operates from a single Day Stay facility at Five Dock (Level 1, 229 Great North Road) and treats patients with complex gastrointestinal conditions including Clostridium difficile infection, ulcerative colitis, Crohn's disease, IBS, Helicobacter pylori, and parasitic infections. CDD is internationally recognised as a digestive diseases centre of excellence and serves both domestic patients (via GP and specialist referrals) and overseas patients through a dedicated international program supported by telehealth consultations on Zoom.

CDD's clinical offering is anchored by Faecal Microbiota Transplantation (FMT), in which it has been a global pioneer since performing its first transplant in 1988 and establishing the world's first faecal bank. The proprietary CDD FMT Protocol, delivered via endoscopic, enema, and bespoke oral capsule (Crapsules) routes, is described as available only at CDD. Supporting services include colonoscopy, panendoscopy/gastroscopy, small bowel capsule endoscopy, infrared coagulation for haemorrhoids, oesophageal dilatation, iron infusion, and CDD's internationally adopted bismuth-based Triple Therapy for H. pylori. The clinic has developed 180+ medical patents, published 220+ scientific papers, and reports over 14,000 FMT procedures performed, with >90% cure rates for C. difficile.

Revenue is generated through professional service fees for consultations, diagnostic procedures, and therapeutic interventions, with FMT priced at A$700 per receiving patient. The donor program (aligned with TGA Standard TGO 105) compensates donors A$40 per deposit. The business model is sales-led and referral-driven: physicians refer patients, direct enquiries are processed through a structured 3-step onboarding, and international patients access the clinic via a dedicated overseas program. No external equity investment, parent company, or subsidiary structure has been disclosed.

Name

Centre for Digestive Diseases

Legal name

Centre for Digestive Diseases

Website

https://centrefordigestivediseases.com

Company type

Private

Founded year

1984

Operating status

Operating

Headcount range

51–100 employees

Short description

Centre for Digestive Diseases is a Sydney-based specialist gastroenterology clinic founded in 1984 by Prof. Thomas Borody, pioneering Faecal Microbiota Transplantation and treating complex GI conditions such as C. difficile, ulcerative colitis, Crohn's disease, and IBS for domestic and international patients.

Ownership category

akta.pro rank

Product category

Specialty Gastroenterology Services

NAICS

Outpatient Care Centers (6214)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

General Gastroenterology (HLAKAEAA)

akta.pro secondary industries

Endoscopy & GI Diagnostic Centers (HLAFAKAG), Outpatient Endoscopy & GI Procedure Centers (Non-ASC) (HLAFABAL), Colorectal Disease & Proctology (HLAKAEAJ), Digestive Oncology (GI Cancer Care) (HLAKAEAF), Nutrition & Malabsorption (Celiac/Short Bowel) (HLAKAEAI)

Keywords

• Gastroenterology services
• Faecal microbiota transplantation
• Endoscopic procedures
• Colorectal cancer screening
• Digestive disease treatment

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain, Others

Revenue model

1. Medical Consultation and Treatment Fees: Revenue from specialist gastroenterology consultations, diagnostic procedures (colonoscopy, endoscopy), and therapeutic treatments provided to patients at the clinic.
2. FMT Procedure Fees: Faecal Microbiota Transplantation procedures generate revenue from receiving patients. The FMT procedure costs the receiving patient $700.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Centre for Digestive Diseases is a specialist gastroenterology day hospital that diagnoses and treats gastrointestinal disorders, anchored by Faecal Microbiota Transplantation (FMT) delivered through its proprietary CDD FMT Protocol via endoscopy, enema, and bespoke faecal capsules (Crapsules). The clinic also provides diagnostic and therapeutic procedures including colonoscopy, panendoscopy/gastroscopy, capsule endoscopy, infrared coagulation for haemorrhoids, oesophageal dilatation, iron infusion, urea breath testing, and CDD-developed Helicobacter pylori triple therapy. Services are delivered in person at the Five Dock (Sydney) clinic and via telehealth, with a structured international patient program and a screened stool donor programme.

Product overview

Centre for Digestive Diseases (CDD) is a specialist gastroenterology clinic offering a unified suite of digestive health services anchored by its proprietary CDD FMT Protocol for Faecal Microbiota Transplantation. The core offering comprises FMT treatments (delivered via endoscopic procedures, enemas, and bespoke capsules called Crapsules) for Clostridium difficile infection, ulcerative colitis, and irritable bowel syndrome. Supporting the FMT program are diagnostic procedures including colonoscopy, panendoscopy/gastroscopy, and capsule endoscopy, alongside treatment procedures such as infrared coagulation for haemorrhoids, oesophageal dilatation, and iron infusion. The clinic also provides H. pylori treatment using its internationally-recognized triple therapy protocol. Services are delivered through both in-person consultations at its Sydney facility and via telehealth using Zoom, with a structured donor program providing screened FMT material. CDD operates as a day hospital with research capabilities and over 180 patents developed for advanced treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• Faecal Microbiota Transplantation (FMT) Restorative gut-microbiota transplant delivered via endoscopic procedures, enema, or capsules for patients with Clostridium difficile infection, ulcerative colitis, Crohn's disease, IBS, and other GI disorders. Priced at $700 per procedure for receiving patients.
• CDD FMT Protocol Proprietary advanced FMT treatment protocol developed at CDD's research labs in collaboration with affiliated international experts. The only medical facility offering this protocol.
• FMT Capsules (Crapsules) Bespoke oral faecal capsules manufactured at CDD's Sydney clinic for daily FMT delivery, used for Crohn's disease and ulcerative colitis as an alternative to endoscopic FMT.
• Colonoscopy Endoscopic examination of the colon for screening, diagnosis, and treatment of colorectal cancer, polyps, and inflammatory bowel disease.
• Panendoscopy (Gastroscopy) Examination of the upper digestive tract (oesophagus, stomach, duodenum) using a flexible endoscope with video camera, supporting biopsy collection and polyp removal.
• Small Bowel Capsule Endoscopy (Pillcam) Swallowable capsule with miniature video camera used to image the small intestine for abnormalities, bleeding, and disease.
• Infrared Coagulation (IRC) Infrared-light-based treatment for haemorrhoids that cuts off blood supply and seals haemorrhoid veins, typically performed alongside colonoscopy.
• Oesophageal Dilatation Procedure performed during panendoscopy to open narrowing of the oesophagus for conditions such as GORD, dysphagia, and eosinophilic oesophagitis.
• Iron Infusion Injection-based iron replenishment treatment for iron deficiency anaemia, requiring approximately 1–2 hours at the clinic.
• Helicobacter pylori Triple Therapy Bismuth-based triple therapy comprising two antibiotics and an acid suppressor, developed at CDD and now the global gold standard for H. pylori eradication and peptic ulcer treatment, including resistant cases.
• Colon Cancer Screening Screening service for colorectal cancer detection using colonoscopy and related diagnostic methods.
• Urea Breath Test Non-invasive breath test for detecting Helicobacter pylori infection and confirming successful eradication treatment.
• Telehealth Consultations Remote patient consultations delivered via Zoom for initial consultations, follow-up, and ongoing care for patients unable to attend the Five Dock clinic in person.
• CDD FMT Donor Program Rigorous stool donor screening and recruitment program aligned with TGA Standard TGO 105; donors follow a whole-food, high-fibre diet and undergo regular health screenings, supplying material used in CDD's FMT procedures.

Quantifiable outcome

• Over 90% cure rate for C. difficile infection with FMT treatment
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• CrestovocoreStrategic or Co-development Partner · 27 June 2017CDD Founder Prof. Thomas Borody is a scientific founder of Crestovo. The partnership is based on foundational clinical research from Dr. Borody and collaborators Dr. Alexander Khoruts and Dr. Michael Sadowsky. Crestovo developed CP101, an oral microbiome therapy derived from this research for treatment of recurrent C. difficile infection. Dr. Borody serves as an active scientific advisor to Crestovo.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• MaaT Pharma: European clinical-stage microbiome therapeutics company developing standardised FMT-derived products for GI-related diseases and oncology. Comparable to CDD's FMT pipeline targeting dysbiosis and IBD indications.
• Seres Therapeutics: Clinical-stage microbiome therapeutics company (Vowst, CP101 lineage) with deep Borody research lineage. Comparable to CDD's R&D output and target indications (recurrent C. difficile, ulcerative colitis) but operating as a pharma developer rather than a clinic.
• Vedanta Biosciences: Microbiome therapeutics developer focused on defined bacterial consortia for GI and immune-mediated diseases. Comparable to CDD's FMT and dysbiosis research focus, but competing from a pharma platform rather than a clinical service model.
• Finch Therapeutics: Microbiome therapeutics company developing Full-Spectrum Microbiota and targeted consortia for GI and autoimmune indications. Overlaps with CDD on FMT-derived approaches to ulcerative colitis and C. difficile.

Direct peers

• Gastro Health: One of the largest US gastroenterology specialty practice networks, offering consults, endoscopy, and infusion services. Comparable to CDD as a multi-physician GI specialty platform with similar procedure mix.
• OpenBiome: US non-profit stool bank and FMT clinical services provider. Comparable to CDD's faecal bank operations and donor screening infrastructure, serving as a similar enabling node in the FMT ecosystem.
• Crestovo (now part of Seres Therapeutics): Microbiome therapeutics company founded on research by Prof. Borody, developing CP101 for recurrent C. difficile. Closely affiliated with CDD through its scientific founder and serves as a translational counterpart to CDD's clinical FMT work.
• Taymount Clinic: UK-based specialist clinic delivering Faecal Microbiota Transplantation for digestive and immune-related conditions. Closest international analogue to CDD with a similar practitioner-led FMT specialty clinic model.

Broad incumbents

• Ferring Pharmaceuticals (Rebyota): Global specialty pharma company that commercialised Rebyota, the first FDA-approved FMT-derived product for recurrent C. difficile. Directly competes with CDD's core C. diff FMT service via a scalable, regulator-approved product.

Others

• Day Hospitals Australia: Industry association representing Australian day hospital facilities. CDD is a member; relevant as an ecosystem reference point for day-hospital operating standards, accreditation, and policy advocacy in Australia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/cdd_au

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centre for Digestive Diseases